AtriCure, Inc. (ATRC)
Every FINRA and SEC series the site collects for AtriCure, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
4.1M
Short interest
settlement 2026-08-31
5.8
Days to cover
+5.6% vs prior
63.0%
Short share of volume
2026-09-17
3
Fails to deliver
settlement 2026-08-25
Wed 28 Oct
Next earnings
estimated; last year 2025-10-29
-$3.0M
Insider flow, 90 days
0 buys, 9 sells
As of 2026-09-17.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 31 August 2026, short interest in ATRC is 4,141,306 shares, up 276,929 shares over the last month. Over the last 48 readings it ranged from 1,172,156 shares (31 January 2025) to 4,864,713 shares (15 July 2026). At the reported average volume of 718K shares a day that is 5.8 days to cover, elevated.
Embed this chartkeeps the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/atrc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 4,141,306 | +5.6% | 718,483 | 5.76 |
| 2026-08-14 | 3,922,615 | +1.5% | 642,538 | 6.10 |
| 2026-07-31 | 3,864,377 | -20.6% | 1,038,652 | 3.72 |
| 2026-07-15 | 4,864,713 | +9.3% | 856,705 | 5.68 |
| 2026-06-30 | 4,449,392 | +29.2% | 1,250,828 | 3.56 |
| 2026-06-15 | 3,443,829 | +1.3% | 706,658 | 4.87 |
| 2026-05-29 | 3,400,672 | -23.2% | 844,268 | 4.03 |
| 2026-05-15 | 4,430,275 | +14.8% | 979,633 | 4.52 |
| 2026-04-30 | 3,857,819 | +6.8% | 809,671 | 4.76 |
| 2026-04-15 | 3,613,453 | +2.1% | 639,424 | 5.65 |
| 2026-03-31 | 3,540,034 | +3.7% | 560,688 | 6.31 |
| 2026-03-13 | 3,414,361 | +8.5% | 609,178 | 5.60 |
| 2026-02-27 | 3,147,385 | -8.7% | 783,134 | 4.02 |
| 2026-02-13 | 3,447,589 | +37.3% | 922,761 | 3.74 |
| 2026-01-30 | 2,510,177 | +0.0% | 464,224 | 5.41 |
| 2026-01-15 | 2,509,848 | +6.0% | 591,125 | 4.25 |
| 2025-12-31 | 2,366,606 | -5.3% | 328,052 | 7.21 |
| 2025-12-15 | 2,499,141 | +8.7% | 621,778 | 4.02 |
| 2025-11-28 | 2,299,662 | -9.9% | 518,274 | 4.44 |
| 2025-11-14 | 2,553,773 | +10.9% | 553,575 | 4.61 |
| 2025-10-31 | 2,303,562 | +12.6% | 584,611 | 3.94 |
| 2025-10-15 | 2,045,448 | -7.3% | 362,079 | 5.65 |
| 2025-09-30 | 2,205,743 | +7.3% | 389,976 | 5.66 |
| 2025-09-15 | 2,056,018 | -1.3% | 479,126 | 4.29 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 17 September 2026, the short share of ATRC volume is 63.0%, down 7.1 points over the last five sessions. Over the last 52 readings it ranged from 30.6% (25 August 2026) to 84.8% (23 July 2026). The latest reading is 3.2 points above the 30-session average of 59.8%, on 626K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-17 | 394K | 626K | 63.0% | 2,417 |
| 2026-09-16 | 276K | 436K | 63.3% | 6 |
| 2026-09-15 | 405K | 566K | 71.6% | 2,500 |
| 2026-09-14 | 272K | 475K | 57.3% | 0 |
| 2026-09-11 | 273K | 491K | 55.6% | 0 |
| 2026-09-10 | 242K | 345K | 70.1% | 0 |
| 2026-09-09 | 373K | 538K | 69.3% | 0 |
| 2026-09-08 | 555K | 742K | 74.8% | 0 |
| 2026-09-04 | 152K | 320K | 47.5% | 0 |
| 2026-09-03 | 324K | 652K | 49.8% | 0 |
| 2026-09-02 | 396K | 526K | 75.3% | 0 |
| 2026-09-01 | 236K | 363K | 65.1% | 0 |
| 2026-08-31 | 135K | 224K | 60.4% | 0 |
| 2026-08-28 | 104K | 187K | 55.6% | 700 |
| 2026-08-27 | 166K | 384K | 43.4% | 22 |
| 2026-08-26 | 195K | 482K | 40.6% | 4,998 |
| 2026-08-25 | 164K | 535K | 30.6% | 0 |
| 2026-08-24 | 111K | 219K | 50.6% | 642 |
| 2026-08-21 | 120K | 185K | 65.1% | 4 |
| 2026-08-20 | 309K | 416K | 74.2% | 0 |
| 2026-08-19 | 189K | 330K | 57.3% | 230 |
| 2026-08-18 | 166K | 309K | 53.6% | 123 |
| 2026-08-17 | 232K | 343K | 67.5% | 503 |
| 2026-08-14 | 89K | 143K | 62.1% | 0 |
| 2026-08-13 | 120K | 188K | 64.1% | 0 |
| 2026-08-12 | 102K | 175K | 58.3% | 76 |
| 2026-08-11 | 157K | 267K | 59.0% | 0 |
| 2026-08-10 | 121K | 206K | 58.5% | 0 |
| 2026-08-07 | 187K | 269K | 69.4% | 400 |
| 2026-08-06 | 237K | 393K | 60.3% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 25 August 2026, the fails-to-deliver balance in ATRC is 3 shares, down 67 shares over the last settlement date. Over the last 52 readings it ranged from 3 shares (25 August 2026) to 49,994 shares (1 October 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-25 | 3 | $49.28 | $148 |
| 2026-08-24 | 70 | $48.98 | $3K |
| 2026-08-20 | 182 | $47.61 | $9K |
| 2026-08-18 | 178 | $44.77 | $8K |
| 2026-08-14 | 30 | $43.49 | $1K |
| 2026-08-13 | 57 | $43.56 | $2K |
| 2026-08-11 | 3,928 | $41.64 | $164K |
| 2026-07-22 | 53 | $34.51 | $2K |
| 2026-07-16 | 222 | $34.54 | $8K |
| 2026-07-07 | 97 | $32.39 | $3K |
| 2026-06-15 | 67 | $28.79 | $2K |
| 2026-06-11 | 876 | $27.51 | $24K |
| 2026-06-08 | 4 | $27.10 | $108 |
| 2026-05-27 | 76 | $28.81 | $2K |
| 2026-05-13 | 12,384 | $26.69 | $331K |
| 2026-03-27 | 7,134 | $30.04 | $214K |
| 2026-03-23 | 69 | $29.18 | $2K |
| 2026-03-19 | 6,000 | $28.85 | $173K |
| 2026-03-06 | 4,285 | $30.31 | $130K |
| 2026-02-26 | 3,226 | $31.19 | $101K |
| 2026-02-19 | 7,214 | $32.26 | $233K |
| 2026-02-09 | 1,083 | $37.11 | $40K |
| 2026-02-04 | 7,857 | $38.07 | $299K |
| 2026-02-03 | 7 | $36.82 | $258 |
| 2026-01-20 | 3,893 | $39.06 | $152K |
| 2026-01-16 | 10,828 | $41.46 | $449K |
| 2026-01-15 | 12,540 | $37.37 | $469K |
| 2025-11-28 | 841 | $36.03 | $30K |
| 2025-11-21 | 3,330 | $33.25 | $111K |
| 2025-11-13 | 1,301 | $33.06 | $43K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at ATRC reported 9 open-market sells worth $3.0M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: GROVES REGINA E on 2026-09-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | GROVES REGINA E | n/a | Sell | 5K | $54.22 | $288K | 35K |
| 2026-09-08 | Privitera Salvatore | Chief Technical Officer | Sell | 4K | $55.00 | $201K | 147K |
| 2026-09-02 | Privitera Salvatore | Chief Technical Officer | Sell | 8K | $52.50 | $408K | 151K |
| 2026-08-24 | Dahlquist Karl S. | Chief Legal Officer | Sell | 9K | $48.89 | $458K | 87K |
| 2026-08-05 | Yuen Maggie | n/a | Sell | 4K | $38.42 | $134K | 14K |
| 2026-08-05 | Prange Karen | n/a | Sell | 4K | $38.80 | $138K | 23K |
| 2026-07-30 | CARREL MICHAEL H | President, CEO, & Director | Gift | 4K | $0.00 | $0 | 774K |
| 2026-07-30 | CARREL MICHAEL H | President, CEO, & Director | Gift | 700 | $0.00 | $0 | 778K |
| 2026-07-29 | Noznesky Justin J | Chief Mktg & Strategy Officer | Sell | 6K | $38.80 | $240K | 100K |
| 2026-07-28 | Doraiswamy Vinayak | Chief Scientific Officer | Sell | 6K | $38.88 | $233K | 87K |
| 2026-07-28 | WEHRWEIN SVEN | n/a | Sell | 25K | $37.84 | $946K | 41K |
| 2026-07-28 | WEHRWEIN SVEN | n/a | Option exercise | 25K | $19.95 | $499K | 66K |
| 2026-05-20 | Prange Karen | n/a | Sell | 3K | $28.65 | $86K | 26K |
| 2026-05-18 | Nachman Shlomo | n/a | Grant | 6K | $0.00 | $0 | 25K |
| 2026-05-18 | Telman Deborah H | n/a | Grant | 6K | $0.00 | $0 | 28K |
| 2026-05-18 | Yuen Maggie | n/a | Grant | 6K | $0.00 | $0 | 18K |
| 2026-05-18 | GROVES REGINA E | n/a | Grant | 6K | $0.00 | $0 | 40K |
| 2026-05-18 | WHITE ROBERT S. | n/a | Grant | 6K | $0.00 | $0 | 128K |
| 2026-05-18 | Prange Karen | n/a | Grant | 6K | $0.00 | $0 | 29K |
| 2026-05-18 | JOHNSON B KRISTINE | n/a | Grant | 6K | $0.00 | $0 | 56K |
| 2026-05-18 | WEHRWEIN SVEN | n/a | Grant | 6K | $0.00 | $0 | 41K |
| 2026-05-15 | Doraiswamy Vinayak | Chief Scientific Officer | Sell | 5K | $28.13 | $141K | 92K |
| 2026-03-12 | Doraiswamy Vinayak | Chief Scientific Officer | Sell | 5K | $29.83 | $149K | 97K |
| 2026-03-10 | WHITE ROBERT S. | n/a | Option exercise | 10K | $14.99 | $150K | 122K |
| 2026-03-06 | CARREL MICHAEL H | President, CEO, & Director | Gift | 1K | $0.00 | $0 | 778K |
| 2026-03-06 | CARREL MICHAEL H | President, CEO, & Director | Gift | 5K | $0.00 | $0 | 779K |
| 2026-03-01 | Doraiswamy Vinayak | Chief Scientific Officer | Tax withholding | 16K | $31.26 | $487K | 102K |
| 2026-03-01 | Doraiswamy Vinayak | Chief Scientific Officer | Grant | 15K | $0.00 | $0 | 117K |
| 2026-03-01 | Doraiswamy Vinayak | Chief Scientific Officer | Grant | 30K | $0.00 | $0 | 102K |
| 2026-03-01 | Dahlquist Karl S. | Chief Legal Officer | Tax withholding | 16K | $31.26 | $490K | 96K |
| 2026-03-01 | Dahlquist Karl S. | Chief Legal Officer | Grant | 15K | $0.00 | $0 | 112K |
| 2026-03-01 | Dahlquist Karl S. | Chief Legal Officer | Grant | 28K | $0.00 | $0 | 97K |
| 2026-03-01 | Wirick Angela L | Chief Financial Officer | Tax withholding | 23K | $31.26 | $718K | 205K |
| 2026-03-01 | Wirick Angela L | Chief Financial Officer | Grant | 23K | $0.00 | $0 | 228K |
| 2026-03-01 | Wirick Angela L | Chief Financial Officer | Grant | 40K | $0.00 | $0 | 205K |
| 2026-03-01 | Noznesky Justin J | Chief Mktg & Strategy Officer | Tax withholding | 16K | $31.26 | $487K | 106K |
| 2026-03-01 | Noznesky Justin J | Chief Mktg & Strategy Officer | Grant | 15K | $0.00 | $0 | 122K |
| 2026-03-01 | Noznesky Justin J | Chief Mktg & Strategy Officer | Grant | 28K | $0.00 | $0 | 107K |
| 2026-03-01 | Seith Douglas J | Chief Operating Officer | Tax withholding | 23K | $31.26 | $717K | 229K |
| 2026-03-01 | Seith Douglas J | Chief Operating Officer | Grant | 26K | $0.00 | $0 | 252K |
| 2026-03-01 | Seith Douglas J | Chief Operating Officer | Grant | 42K | $0.00 | $0 | 227K |
| 2026-03-01 | Privitera Salvatore | Chief Technical Officer | Tax withholding | 13K | $31.26 | $410K | 158K |
| 2026-03-01 | Privitera Salvatore | Chief Technical Officer | Grant | 15K | $0.00 | $0 | 171K |
| 2026-03-01 | Privitera Salvatore | Chief Technical Officer | Grant | 30K | $0.00 | $0 | 156K |
| 2026-03-01 | CARREL MICHAEL H | President, CEO, & Director | Tax withholding | 73K | $31.26 | $2.3M | 784K |
| 2026-03-01 | CARREL MICHAEL H | President, CEO, & Director | Grant | 101K | $0.00 | $0 | 857K |
| 2026-03-01 | CARREL MICHAEL H | President, CEO, & Director | Grant | 69K | $0.00 | $0 | 756K |
| 2025-12-31 | Seith Douglas J | Chief Operating Officer | Grant | 257 | $27.37 | $7K | 184K |
| 2025-12-10 | CARREL MICHAEL H | President, CEO, & Director | Gift | 4K | $0.00 | $0 | 687K |
| 2025-11-26 | Noznesky Justin J | Chief Mktg & Strategy Officer | Sell | 5K | $37.29 | $193K | 79K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON16 Form 144 notices on file for ATRC worth $4.1M at the prices reported; 9 in the last 90 days worth $3.1M. Latest: GROVES REGINA E filed on 2026-09-11 to sell 5,313 shares ($285K) from 2026-09-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-11 | GROVES REGINA EDirector | 5K | $285K | 0.010% | 2026-09-10 | Fidelity Brokerage Services LLC |
| 2026-09-08 | SALVATORE PRIVITERAOfficer | 4K | $201K | 0.007% | 2026-09-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-02 | SALVATORE PRIVITERAOfficer | 8K | $408K | 0.015% | 2026-09-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-24 | KARL DAHLQUISTOfficer | 9K | $458K | 0.018% | 2026-08-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-05 | Prange KarenDirector | 4K | $139K | 0.007% | 2026-08-05 | Fidelity Brokerage Services LLC |
| 2026-08-05 | MAGGIE YUENDirector | 4K | $134K | 0.007% | 2026-08-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-29 | Noznesky Justin JOfficer | 6K | $240K | 0.012% | 2026-07-29 | RBC CAPITAL MARKETS LLC |
| 2026-07-28 | VINAYAK DORAISWAMYOfficer | 6K | $233K | 0.012% | 2026-07-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-28 | SVEN WEHRWEINDirector | 25K | $964K | 0.049% | 2026-07-28 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-20 | Prange KarenDirector | 3K | $86K | 0.006% | 2026-05-20 | Fidelity Brokerage Services LLC |
| 2026-05-15 | VINAYAK DORAISWAMYOfficer | 5K | $141K | 0.010% | 2026-05-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | VINAYAK DORAISWAMYOfficer | 5K | $149K | 0.010% | 2026-03-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-26 | Noznesky Justin JOfficer | 5K | $193K | 0.010% | 2025-11-26 | RBC CAPITAL MARKETS LLC |
| 2025-11-25 | SVEN WEHRWEINDirector | 5K | $189K | 0.010% | 2025-11-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-24 | SVEN WEHRWEINDirector | 5K | $188K | 0.010% | 2025-11-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-21 | MAGGIE YUENDirector | 3K | $107K | 0.006% | 2025-11-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON13 holders above 5% have filed on ATRC, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 7.8% of the class (3,862,837 shares), filed 2025-10-17 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 3 | AllianceBernstein L.P.investment adviser | 2.8M | 5.5% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Wellington Management Group LLPparent holding company | 3.4M | 6.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Wellington Investment Advisors Holdings LLPparent holding company | 3.4M | 6.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Wellington Group Holdings LLPparent holding company | 3.4M | 6.8% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Wellington Management Company LLPinvestment adviser | 3.4M | 5.5% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 2.5M | 5.1% | 2026-03-31 |
| 2026-04-28 | 13G | Vanguard Portfolio Managementinvestment adviser | 2.7M | 5.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 2 | Hood River Capital Management LLCinvestment adviser | 3.1M | 6.2% | 2025-12-31 |
| 2025-11-13 | 13G/Ano. 1 | Macquarie Investment Management Business Trustinvestment adviser | 2.3M | 4.6% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Macquarie Management Holdings Incparent holding company | 2.3M | 4.6% | 2025-09-30 |
| 2025-11-13 | 13G/Ano. 1 | Macquarie Group Limitedparent holding company | 2.3M | 4.6% | 2025-09-30 |
| 2025-10-17 | 13G/Ano. 8 | BlackRock, Inc.parent holding company | 3.9M | 7.8% | 2025-09-30 |
13F holders
Tracked managers holding ATRC at their latest 13F. JSON7 of the 30 tracked managers held ATRC at their latest 13F, $66.2M in total at quarter-end prices. Point72 Asset Management is the largest at $16.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 604K | $16.9M | 0.02% | +326K |
| AQR Capital Management | 2026-06-30 | 544K | $15.2M | 0.01% | +358K |
| Two Sigma Investments | 2026-06-30 | 526K | $14.7M | 0.01% | -225K |
| Renaissance Technologies | 2026-06-30 | 234K | $6.6M | 0.01% | -75K |
| D. E. Shaw & Co. | 2026-06-30 | 193K | $5.4M | 0.00% | +136K |
| Citadel Advisors | 2026-06-30 | 189K | $5.3M | 0.00% | +101K |
| Bridgewater Associates | 2026-06-30 | 76K | $2.1M | 0.01% | +43K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) AtriCure, Inc. reported revenue of $153.6M, up 12.8% from the same quarter a year earlier, and net income of $9.0M (0.18 diluted EPS). In FY 2025 it generated $57.3M of operating cash flow. As of 2026-06-30, cash was $167.8M against $61.0M of debt.
- Cash
- $167.8M
- Debt
- $61.0M
- Equity
- $516.4M
- Total assets
- $676.6M
- Shares outstanding
- 50,866,294
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $153.6M | $9.0M | 5.8% | 0.18 |
| Q1 2026 | 2026-03-31 | $141.2M | $108K | 0.1% | 0.00 |
| Q4 2025derived | 2025-12-31 | $140.5M | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $134.3M | -$267K | -0.2% | -0.01 |
| Q2 2025 | 2025-06-30 | $136.1M | -$6.2M | -4.5% | -0.13 |
| Q1 2025 | 2025-03-31 | $123.6M | -$6.7M | -5.5% | -0.14 |
| Q4 2024derived | 2024-12-31 | $124.3M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $115.9M | -$7.9M | -6.8% | -0.17 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $534.5M | n/a | $57.3M | $9.1M | n/a | n/a |
| FY 2024 | 2024-12-31 | $465.3M | n/a | $12.2M | $11.5M | n/a | n/a |
| FY 2023 | 2023-12-31 | $399.2M | n/a | $4.5M | $12.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $330.4M | n/a | -$22.1M | $16.9M | n/a | n/a |
| FY 2021 | 2021-12-31 | $274.3M | n/a | -$13.8M | $9.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-22 from the cover page.
What this page is
AtriCure, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows AtriCure, Inc. (ATRC), SEC CIK 1323885, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-17.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-25.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-11.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K Item 2.02 (full-text search)EDGAR full-text search read twice a day; the estimate is last year's date plus 52 weeks. Latest 2026-07-23.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1323885Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 18 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
- BSXBOSTON SCIENTIFIC CORP
- TNDMTANDEM DIABETES CARE INC
- DXCMDEXCOM INC
- PENPenumbra Inc
- SIBNSI-BONE, Inc.
- MMM3M CO
- LMATLEMAITRE VASCULAR INC
- INSPInspire Medical Systems, Inc.
- NVCRNovoCure Ltd
- RMDRESMED INC
- SYKSTRYKER CORP
- GKOSGLAUKOS Corp
- IRTCiRhythm Holdings, Inc.
- ICUIICU MEDICAL INC/DE
- ATECAlphatec Holdings, Inc.
- AORTARTIVION, INC.
- PODDINSULET CORP
- BDXBECTON DICKINSON & CO
- IRMDIRADIMED CORP
- UFPTUFP TECHNOLOGIES INC
- LUNGPulmonx Corp
- MMSIMERIT MEDICAL SYSTEMS INC
- ANGOANGIODYNAMICS INC
- OFIXOrthofix Medical Inc.
Datasets
Frequently Asked Questions
How much of ATRC is sold short?
What is ATRC's daily short volume?
Does ATRC have fails to deliver?
Are ATRC insiders buying or selling?
Have ATRC insiders filed to sell?
Who owns more than 5% of ATRC?
What did ATRC report last quarter?
Which funds hold ATRC?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.